Montalban X, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. PR2086. EAN 2017.
De impact van heterogene patronen van spierzwakte op uitkomstmaten en diagnose
feb 2020